These new molecules, evaluated as Blockbuster in the Signature Square, could revolutionize the treatment of Huntington's disease and other neurodegenerative diseases.
Boston, MA (PRWEB) January 30, 2016
One Million Solutions in Health™ is pleased to announce that new molecules to revolutionize the treatment of Huntington’s disease, based on Dr. Lori Griner’s work from the NIH, received the top designation of Blockbuster. This means the technology was highly ranked in both its Market or Partner Readiness and its Value Proposition to the Marketplace.
One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ Office of Technology Transfer at the National Institutes of Health (NIH) to increase awareness and understanding of NIH technologies among potential partners in the life science and healthcare industries.
The Signature Square™ program brings together Subject Matter Experts to evaluate new or established scientific technology. The Signature Square™ program provides feedback to commercial providers and academics on technology in the healthcare or life science industry. The vendor or scientist discusses their solution during a live webinar presentation with an audience of relevant Subject Matter Experts. In Dr. Griner’s case, the experts were from pharmaceutical and biotechnology companies, along with other academic scientists from around the world who evaluated these molecules to revolutionize the treatment of Huntington’s disease.
The Signature Square™ evaluation is based on several criteria that summarize a new or established technology’s Market Readiness and Value Proposition to the Marketplace. The final outcome of each evaluation results in a ranking: Blockbuster, Upstart, Novel or Innovator. This is an opportunity for technology providers to receive direct evaluation, which can be used to inform potential investors and partners.
“The industry clearly sees a need for Dr. Griner’s technology,” said Dawn Van Dam, President and CEO of One Million Solutions in Health, “We have never seen a ranking so high for a technology’s Value to the Marketplace. We anticipate Dr. Griner will be very successful with this technology.”
Dr. Griner’s discovery is a novel, highly effective, family of five autophagic inducers (A.I. compounds). These A.I. compounds have the potential to fulfill the hypothesis that inducing autophagy in patients with Huntington’s disease (HD) can clear mHtt aggregates, which cause the disorder.
Dr. Griner received positive and constructive feedback from the industry, which will allow her to continue to develop her science and find partners to bring it to commercial use. Dr. Griner has received a final report detailing the Subject Matter Expert’s feedback. One example is as follows: “It has a lot of potential, not only in therapeutic applications, but also in basic research in the lab.” – Feedback from a Subject Matter Expert
For those interested in working with Dr. Griner to bring these molecules to revolutionize the treatment of Huntington’s disease to the market, please contact Dawn Van Dam, President of One Million Solutions in Health to be put in touch with the appropriate NIH contacts.
Alternatively, if you would like to see the details of the full Report and a recording of the Signature Square™ presentation, please contact us for more details on how individuals or companies can join the Technology Evaluation Consortium™ and have full access to all of our Signature Square™ evaluations.
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM
The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
ABOUT DR. LORI GRINER
Dr. Lori Griner earned her Bachelor’s and Master’s degrees in biology from Wayne State University in Detroit, Michigan. She subsequently completed her Ph.D. at the University of South Florida/Moffitt Cancer Center in Tampa, Florida in 2012. Research from her Ph.D. dissertation showed that cholesterol depletion in myeloproliferative neoplasms (MPNs) impaired dysregulated JAK/STAT signaling and improved the killing of neoplastic cells, highlighting the vulnerability of cholesterol in MPNs.
Currently, as a post-doctoral research fellow in the laboratory of Dr. Melvin L. DePamphilis at the National Institutes of Health, Dr. Griner has initiated, designed, conducted, and led multiple research projects involving the discovery and investigation of the therapeutic potential of a family of autophagic inducers in Huntington’s disease, a neurodegenerative disease caused by the expression of mutated huntingtin protein. This work has led to publications, patent applications, ‘Excellence in Research’ awards, national conference presentations, and travel opportunities.
Dawn Van Dam
President and CEO